Trial Profile
A Multicenter, Randomized, Controlled Trial of Combination Therapy for HBeAg Positive Chronic Hepatitis B: Comparing Thymosin Alpha 1 and Pegylated Interferon-alpha2a With Pegylated Interferon-alpha2a Alone.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Dec 2012
Price :
$35
*
At a glance
- Drugs Thymalfasin (Primary) ; Peginterferon alfa-2a
- Indications Hepatitis B
- Focus Therapeutic Use
- 20 Jul 2011 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.
- 20 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Oct 2006 New trial record.